Literature DB >> 25304284

Intravitreal Ranibizumab as Palliative Therapy for Iris Metastasis Complicated With Refractory Secondary Glaucoma.

Olga E Makri1, Chara Psachoulia, Artemis Exarchou, Constantinos D Georgakopoulos.   

Abstract

PURPOSE: To report a case where iris metastasis was the presenting sign of hitherto undiagnosed non-small cell lung carcinoma. The diagnostic approach and patient management are discussed.
METHODS: A 51-year-old man presented with pain due to an iris mass and neovascular glaucoma.
RESULTS: Systemic evaluation subsequently led to the diagnosis of non-small cell lung carcinoma and the iris mass was considered metastatic. The patient refused any systemic therapy and accepted only intervention for ocular pain relief. Ranibizumab was administered intravitreally and resulted in subsidence of iris mass and new vessels and pain relief, which enhanced the patient's quality of life.
CONCLUSIONS: This is the first known report where intravitreal injection of ranibizumab was used as palliative treatment for refractory neovascular glaucoma due to iris metastasis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 25304284     DOI: 10.1097/IJG.0000000000000163

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  3 in total

1.  Effectiveness of micropulse transscleral laser therapy in uncontrolled glaucoma secondary to ciliary body metastasis.

Authors:  Pukkapol Suvannachart; Patcharaporn Jaru-Ampornpan; Sunee Chansangpetch; Anita Manassakorn; Visanee Tantisevi; Kitiya Ratanawongphaibul
Journal:  Am J Ophthalmol Case Rep       Date:  2021-08-08

2.  Intravitreal bevacizumab as therapy for refractory neovascular glaucoma secondary to iris metastasis of breast carcinoma.

Authors:  Stephanie Vale; Lorena Montalvo; Emilio Baez; Armando L Oliver
Journal:  Am J Ophthalmol Case Rep       Date:  2018-01-04

3.  A Case Report of Intravitreal Bevacizumab for Iris Metastasis of Small Cell Lung Carcinoma with Neovascular Glaucoma.

Authors:  Takako Hidaka; Hideki Chuman; Nobuhisa Nao-I
Journal:  Case Rep Ophthalmol       Date:  2018-08-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.